Jointly sponsored by the University of Cincinnati and Princeton CME

Target Audience

This activity is designed for managed markets physicians and pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

• Describe the incidence and burden of cystic fibrosis (CF)
• Outline the currently available pharmacotherapies for the management of pancreatic exocrine insufficiency in CF
• Assess the potential impact of FDA requirements for pancreatic enzyme products on CF management strategies
• Apply the evidence to ensure the safe and effective management of pancreatic exocrine insufficiency in CF

Credit Eligibility

To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: October 5, 2007; Expiration Date: October 5, 2008

Estimated time to complete: 1 hour

There is no fee associated with this activity.

Lecture Components

The presentation slides, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.

CME Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and Princeton CME. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 hour credit (0.1 CEU) of continuing pharmacy education (ACPE #452-999-07-023-H01).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity sponsored or cosponsored by Princeton CME may contact the Assistant Director of Continuing Education in writing. The Assistant Director of Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Director of Continuing Education may be made for a second level of review.

Grant Support

Supported by an educational grant from Solvay Pharmaceuticals, Inc.

Participating Faculty

M. James Lopez, MD
Associate Professor
Medical Director
Pediatric Liver Disease and Transplantation
Department of Pediatrics and Communicable Diseases
University of Michigan
Ann Arbor, Michigan

Robert J. Kuhn, PharmD
Professor of Pharmacy Practice and Pediatrics
Colleges of Pharmacy and Medicine
University of Kentucky
Lexington, Kentucky

Independent Clinical Reviewer

Christopher M. Oermann, MD
Associate Professor of Pediatrics
Director, Pediatric Pulmonary Fellowship Training Program
Baylor College of Medicine
Houston, Texas

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of the University of Cincinnati and Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity.  All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest.  If a conflict is identified, it is the responsibility of the University of Cincinnati and Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
 
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Lopez: Has disclosed no relevant financial relationships with any commercial interests.

Dr. Kuhn: Speaker—Axcan, Wyeth; Consultant—Novartis. 

Dr. Oermann: Principal investigator, research funding—Cystic Fibrosis Foundation, Lilead, Inspire, Altus (funds paid to Baylor College of Medicine).

Planning Committee Kay Weigand, University of Cincinnati, Randy Robbin and John Savage, Princeton CME; Rosemary Hodgson, William Kormos, and Rob Brosen, Princeton Media Associates have disclosed no relevant financial relationships with any commercial interests.

The University of Cincinnati and Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.

The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.

Some of the clinical studies discussed in this activity may have been funded by manufacturers of drugs or devices.